Richard C. Malabre's most recent trade in Akebia Therapeutics Inc. was a trade of 15,000 Common Stock done at an average price of $4.0 . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | Richard C. Malabre | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 4.01 per share. | 09 Jun 2025 | 15,000 | 266,914 (0%) | 0% | 4.0 | 60,150 | Common Stock |
| Akebia Therapeutics Inc. | Richard C. Malabre | SVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 15,000 | 321,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Richard C. Malabre | SVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 09 Jun 2025 | 15,000 | 281,914 (0%) | 0% | 1.7 | 25,200 | Common Stock |
| Akebia Therapeutics Inc. | Richard C. Malabre | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 3.53 per share. | 04 Jun 2025 | 13,334 | 266,914 (0%) | 0% | 3.5 | 47,069 | Common Stock |
| Akebia Therapeutics Inc. | Richard C. Malabre | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 128,000 | 128,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Richard C. Malabre | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 85,000 | 310,450 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Richard C. Malabre | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 2.10 per share. | 31 Jan 2025 | 30,202 | 280,248 (0%) | 0% | 2.1 | 63,424 | Common Stock |
| Akebia Therapeutics Inc. | Richard Malabre C. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 336,000 | 336,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Richard Malabre C. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 223,950 | 223,950 (0%) | 0% | 0 | Common Stock |